Roles of Adenosine Monophosphate-Activated Protein Kinase (AMPK) in the Kidney
The kidney is a metabolically active organ with high energy demands, making it particularly vulnerable to disruptions in energy homeostasis. Adenosine monophosphate (AMP)-activated protein kinase (AMPK), a serine/threonine kinase, serves as a central energy sensor and regulator of cellular metabolism. In the kidney, AMPK orchestrates a wide range of physiological processes, including lipid and glucose metabolism, mitochondrial dynamics, autophagy, inflammation, fibrosis, and ion transport. Dysregulation of AMPK signaling contributes to the pathogenesis of kidney diseases, underscoring its potential as a therapeutic target.
Structure and Activation of AMPK
AMPK exists as a heterotrimeric complex composed of a catalytic α-subunit and regulatory β- and γ-subunits. Activation occurs in response to energy stress, marked by an increased AMP:ATP or ADP:ATP ratio. Upstream kinases, such as liver kinase B1 (LKB1) and calcium/calmodulin-dependent protein kinase kinase beta (CaMKKβ), phosphorylate the α-subunit at Thr172, triggering AMPK activation. Additional regulators include protein kinase B (AKT), protein kinase A (PKA), and transforming growth factor (TGF)-β-activated kinase-1. These pathways integrate metabolic and hormonal signals to fine-tune AMPK activity in renal cells.
AMPK in Lipid Metabolism
AMPK critically regulates lipid metabolism by balancing synthesis, oxidation, and storage. It suppresses fatty acid (FA) synthesis by phosphorylating and inhibiting acetyl-CoA carboxylase (ACC), the rate-limiting enzyme in FA production. Simultaneously, AMPK enhances FA β-oxidation by downregulating carnitine palmitoyltransferase-1 (CPT-1), which transports FAs into mitochondria. This dual action shifts cellular metabolism toward energy generation during nutrient scarcity.
Cholesterol synthesis is also modulated by AMPK through inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme in the mevalonate pathway. Furthermore, AMPK suppresses lipogenesis by phosphorylating sterol regulatory element-binding protein 1c (SREBP1c), a transcription factor driving lipogenic gene expression.
Lipotoxicity, a hallmark of renal injury in metabolic disorders, is mitigated by AMPK through regulation of CD36, a FA translocase. Overexpression of CD36 exacerbates lipid accumulation and renal damage, while AMPK activation reduces CD36-mediated FA uptake, alleviating lipotoxicity.
AMPK in Glucose Metabolism
AMPK enhances cellular glucose uptake by promoting the translocation of glucose transporters GLUT1 and GLUT4 to the plasma membrane. In renal cells, the transient receptor potential cation channel 6 (TRPC6)-AMPK axis facilitates insulin-dependent glucose uptake, linking ion channel activity to metabolic regulation.
Glycolysis is stimulated by AMPK via activation of phosphofructokinase 2 (PFK2), which increases fructose-2,6-bisphosphate levels, a potent activator of phosphofructokinase 1 (PFK1), the rate-limiting glycolytic enzyme. Conversely, AMPK inhibits glycogen synthesis by phosphorylating glycogen synthase (GS), reducing glycogen storage.
Gluconeogenesis is suppressed by AMPK through inhibition of CREB-regulated transcription coactivator 2 (CRTC2) and hepatocyte nuclear factor 4α (HNF4α), key regulators of phosphoenolpyruvate carboxykinase (PEPCK), a rate-limiting enzyme in glucose production. AMPK also ameliorates insulin resistance by modulating phosphatase and tensin homolog (PTEN) activity and enhancing crosstalk with sirtuin 1 (SIRT1), a NAD+-dependent deacetylase involved in metabolic adaptation.
AMPK in Mitochondrial Dynamics
Mitochondrial homeostasis is vital for renal energy production, and AMPK regulates mitochondrial biogenesis, dynamics, and quality control. AMPK activates peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α), a master regulator of mitochondrial biogenesis. PGC1α induces expression of nuclear respiratory factors 1 and 2 (NRF1/2) and transcription factor A, mitochondrial (TFAM), which drive mitochondrial DNA replication and respiratory chain assembly.
Mitochondrial fission and fusion are balanced by AMPK through modulation of dynamin-related proteins, such as mitochondrial fission factor (MFF) and mitofusin 1 (MFN1). Phosphorylation of MFF by AMPK promotes mitochondrial fission, facilitating the removal of damaged organelles via mitophagy. AMPK further enhances mitophagy by activating unc-51-like autophagy activating kinase 1 (ULK1) and inhibiting mechanistic target of rapamycin (mTOR), a suppressor of autophagy.
AMPK in Autophagy
Autophagy, a cellular recycling process, is crucial for maintaining renal homeostasis under stress. AMPK activates autophagy by phosphorylating ULK1, initiating autophagosome formation, and suppressing mTOR activity. The tuberous sclerosis complex 2 (TSC2), a negative regulator of mTOR, is phosphorylated by AMPK, further inhibiting mTOR complex 1 (mTORC1).
AMPK also interacts with SIRT1 to enhance autophagy. By increasing cellular NAD+ levels, AMPK activates SIRT1, which deacetylates forkhead box O (FOXO) transcription factors, promoting autophagic gene expression. This synergy between AMPK and SIRT1 ensures efficient clearance of damaged organelles and proteins, protecting renal cells from injury.
AMPK in Inflammation and Fibrosis
Chronic kidney diseases, including diabetic nephropathy, are characterized by inflammation and fibrosis. AMPK attenuates these processes by reducing macrophage infiltration, modulating polarization toward anti-inflammatory phenotypes, and suppressing oxidative stress. NADPH oxidase 4 (NOX4), a major source of reactive oxygen species (ROS) in the kidney, is downregulated by AMPK, while antioxidant genes like superoxide dismutase 2 (SOD2) and catalase are upregulated.
AMPK exerts anti-fibrotic effects by inhibiting profibrotic signaling pathways. For instance, AMPK disrupts casein kinase 2 beta (CK2β)-mediated activation of pro-fibrotic transcription factors, reducing extracellular matrix deposition. These actions highlight AMPK’s role in mitigating progressive renal scarring.
AMPK in Ion Transport
Renal ion channels and transporters are tightly regulated by AMPK to maintain electrolyte balance. The epithelial sodium channel (ENaC) is modulated via AMPK-dependent phosphorylation of neural precursor cell expressed, developmentally downregulated 4-like (NEDD4-2), an E3 ubiquitin ligase that promotes ENaC degradation. AMPK also enhances Na+–K+–ATPase (NKA) activity by restoring its surface expression in proximal tubules.
In the thick ascending limb, AMPK activates Na+–K+–2Cl– cotransporter 2 (NKCC2), influencing salt reabsorption. Additionally, AMPK regulates cystic fibrosis transmembrane conductance regulator (CFTR) chloride channels through PKA-dependent mechanisms, linking energy status to fluid secretion.
AMPK in Energy-Sensing Networks
AMPK operates within an integrated network involving SIRT1 and PGC1α to coordinate energy metabolism. The AMPK/SIRT1/PGC1α axis promotes mitochondrial biogenesis and oxidative metabolism while counteracting oxidative stress. SIRT3, a mitochondrial sirtuin activated by PGC1α, enhances ATP synthesis by optimizing electron transport chain efficiency and FA oxidation. This triad ensures mitochondrial adaptability during energy fluctuations.
Therapeutic Implications
Pharmacological activation of AMPK holds promise for treating kidney diseases, particularly those linked to metabolic dysfunction. Indirect activators like metformin and canagliflozin inhibit mitochondrial complex I, elevating AMP:ATP ratios and activating AMPK. Metformin is widely used in diabetic kidney disease but carries a risk of lactic acidosis. Canagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, shows renoprotective effects via AMPK-dependent mechanisms.
Natural compounds, such as resveratrol, activate AMPK through multiple pathways, including SIRT1 activation and ATP synthase inhibition. Preclinical studies demonstrate that resveratrol and the direct AMPK agonist AICAR attenuate acute kidney injury and diabetic nephropathy, though clinical translation remains pending. A769662, a direct AMPK activator binding the α/β-subunit interface, exhibits therapeutic potential but suffers from poor bioavailability.
Conclusion
AMPK serves as a multifunctional regulator of renal energy metabolism, mitochondrial integrity, autophagy, inflammation, and ion transport. Its central role in maintaining cellular homeostasis underscores its importance in both renal physiology and disease. While AMPK-targeted therapies offer exciting opportunities, challenges in drug specificity, safety, and delivery must be addressed. Future research should focus on optimizing AMPK agonists to harness their full therapeutic potential in kidney diseases.
doi.org/10.1097/CM9.0000000000001831
Was this helpful?
0 / 0